Composition of Matter Patent for QN-302 Granted by United

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences...

Related Keywords

United States ,Jules Abraham ,Michael Poirier ,Exchange Commission ,European Patent Office ,Partners Inc ,Qualigen Therapeutics Inc ,Aboutqualigentherapeutics Inc ,Nasdaq ,Trademarks Office ,Orphan Drug Designation ,United States Patent ,Investigational New Drug ,Gastrointestinal Stromal Tumors ,Drug Designation ,Qualigen Therapeutics ,Fast Track ,Orphan Drug ,Private Securities Litigation Reform Act ,Nasdaq Qlgn ,Nc ,Algn ,N 302 ,Ancreaticcancer ,